Jacobs Levy Equity Management Inc. Invests $703,000 in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Jacobs Levy Equity Management Inc. bought a new stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 232,058 shares of the company's stock, valued at approximately $703,000. Jacobs Levy Equity Management Inc. owned about 0.33% of Zentalis Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. Voya Investment Management LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 14.1% during the fourth quarter. Voya Investment Management LLC now owns 57,017 shares of the company's stock valued at $173,000 after purchasing an additional 7,058 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Zentalis Pharmaceuticals by 26.8% during the fourth quarter. Wells Fargo & Company MN now owns 34,609 shares of the company's stock valued at $105,000 after acquiring an additional 7,305 shares in the last quarter. Corton Capital Inc. bought a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter valued at approximately $32,000. Northern Trust Corp increased its position in shares of Zentalis Pharmaceuticals by 2.2% during the fourth quarter. Northern Trust Corp now owns 484,738 shares of the company's stock valued at $1,469,000 after acquiring an additional 10,513 shares in the last quarter. Finally, Federated Hermes Inc. increased its position in shares of Zentalis Pharmaceuticals by 2.2% during the fourth quarter. Federated Hermes Inc. now owns 493,982 shares of the company's stock valued at $1,497,000 after acquiring an additional 10,644 shares in the last quarter.

Analyst Ratings Changes

ZNTL has been the subject of several analyst reports. Wedbush reissued a "neutral" rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. UBS Group reduced their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. Finally, Wells Fargo & Company reduced their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $8.24.

Insider Transactions at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers purchased 21,000 shares of the company's stock in a transaction dated Wednesday, April 30th. The shares were acquired at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the purchase, the director now directly owns 281,192 shares of the company's stock, valued at $393,668.80. The trade was a 8.07% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.90% of the company's stock.

Zentalis Pharmaceuticals Trading Down 3.2%

NASDAQ:ZNTL traded down $0.04 during trading hours on Friday, reaching $1.20. The company had a trading volume of 778,244 shares, compared to its average volume of 1,554,957. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.01 and a 52 week high of $13.00. The firm has a market cap of $86.34 million, a price-to-earnings ratio of -0.48 and a beta of 1.81. The firm's 50 day moving average price is $1.38 and its 200-day moving average price is $2.26.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting analysts' consensus estimates of ($0.67). On average, analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.